Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 30;213(6):1011–1028. doi: 10.1084/jem.20151183

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Zhang et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 5. — Functional complementation. (A) Phleo sensitivity of U20S cells, in which the ERCC6L2 gene has been disrupted through CRISPR/Cas9 technology, compared with the sensitivity of the WT parental cells and a U2OS line with mutated DNA ligase IV. This experiment was performed three times. (B) Functional complementation of phleo sensitivity provided by WT Hebo transduced into the patient’s cells as compared with the ERCC6L2-SF or empty vector. A mix population of transduced (GFP⁺) and untransduced (GFP⁻) was analyzed through multicolor competition assay (Smogorzewska et al., 2007). The selective growth advantage is scored as the increase in the index of GFP-positive cells/GFP-negative cells at various times compared with the initiation of the culture (index = 1). This experiment was performed two times. Data are mean ± SEM. (C) Sensitivity of the patient’s cells to phleo after Hebo, ERCC6L2-SF, or mock transduction. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 for a Mann-Whitney test. This experiment was performed three times. (D) Expression level of Hebo and ERCC6L2-SF after transient transfection into 293T cells, revealed with anti-V5 antibody. WB, Western blot.